These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 15375026)
1. Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle. Lessard SJ; Lo Giudice SL; Lau W; Reid JJ; Turner N; Febbraio MA; Hawley JA; Watt MJ Endocrinology; 2004 Dec; 145(12):5665-70. PubMed ID: 15375026 [TBL] [Abstract][Full Text] [Related]
2. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone. Nadeau KJ; Ehlers LB; Aguirre LE; Reusch JE; Draznin B Diabetes Obes Metab; 2007 Sep; 9(5):714-23. PubMed ID: 17697064 [TBL] [Abstract][Full Text] [Related]
3. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. Lee JS; Pinnamaneni SK; Eo SJ; Cho IH; Pyo JH; Kim CK; Sinclair AJ; Febbraio MA; Watt MJ J Appl Physiol (1985); 2006 May; 100(5):1467-74. PubMed ID: 16357064 [TBL] [Abstract][Full Text] [Related]
4. Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. Coort SL; Coumans WA; Bonen A; van der Vusse GJ; Glatz JF; Luiken JJ J Lipid Res; 2005 Jun; 46(6):1295-302. PubMed ID: 15772429 [TBL] [Abstract][Full Text] [Related]
5. Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. Lessard SJ; Chen ZP; Watt MJ; Hashem M; Reid JJ; Febbraio MA; Kemp BE; Hawley JA Am J Physiol Endocrinol Metab; 2006 Feb; 290(2):E251-7. PubMed ID: 16118254 [TBL] [Abstract][Full Text] [Related]
6. In obese rat muscle transport of palmitate is increased and is channeled to triacylglycerol storage despite an increase in mitochondrial palmitate oxidation. Holloway GP; Benton CR; Mullen KL; Yoshida Y; Snook LA; Han XX; Glatz JF; Luiken JJ; Lally J; Dyck DJ; Bonen A Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E738-47. PubMed ID: 19141681 [TBL] [Abstract][Full Text] [Related]
7. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047 [TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones influence plasma steroids of male obese Zucker rats. Fürnsinn C; Nowotny P; Brunmair B; Gras F; Roden M; Waldhäusl W; Vierhapper H Endocrinology; 2002 Jan; 143(1):327. PubMed ID: 11751625 [TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle lipogenic protein expression is not different between lean and obese individuals: a potential factor in ceramide accumulation. Thrush AB; Brindley DN; Chabowski A; Heigenhauser GJ; Dyck DJ J Clin Endocrinol Metab; 2009 Dec; 94(12):5053-61. PubMed ID: 19837942 [TBL] [Abstract][Full Text] [Related]
10. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Jucker BM; Schaeffer TR; Haimbach RE; McIntosh TS; Chun D; Mayer M; Ohlstein DH; Davis HM; Smith SA; Cobitz AR; Sarkar SK Diabetes; 2002 Jul; 51(7):2066-73. PubMed ID: 12086934 [TBL] [Abstract][Full Text] [Related]
11. Metabolic profiling of muscle contraction in lean compared with obese rodents. Thyfault JP; Cree MG; Tapscott EB; Bell JA; Koves TR; Ilkayeva O; Wolfe RR; Dohm GL; Muoio DM Am J Physiol Regul Integr Comp Physiol; 2010 Sep; 299(3):R926-34. PubMed ID: 20504904 [TBL] [Abstract][Full Text] [Related]
12. Postexercise muscle triacylglycerol and glycogen metabolism in obese insulin-resistant zucker rats. Bruce CR; Lee JS; Kiens B; Hawley JA Obes Res; 2004 Jul; 12(7):1158-65. PubMed ID: 15292481 [TBL] [Abstract][Full Text] [Related]
13. Increased fatty acid uptake and altered fatty acid metabolism in insulin-resistant muscle of obese Zucker rats. Turcotte LP; Swenberger JR; Zavitz Tucker M; Yee AJ Diabetes; 2001 Jun; 50(6):1389-96. PubMed ID: 11375340 [TBL] [Abstract][Full Text] [Related]
14. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762 [TBL] [Abstract][Full Text] [Related]
15. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174 [TBL] [Abstract][Full Text] [Related]
16. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648 [TBL] [Abstract][Full Text] [Related]
17. Isomer-specific actions of conjugated linoleic acid on muscle glucose transport in the obese Zucker rat. Henriksen EJ; Teachey MK; Taylor ZC; Jacob S; Ptock A; Krämer K; Hasselwander O Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E98-E105. PubMed ID: 12618357 [TBL] [Abstract][Full Text] [Related]
19. Acute exposure to rosiglitazone does not affect glucose transport in intact human skeletal muscle. Skrobuk P; Kuoppamaa H; Hiukka A; Koistinen HA Metabolism; 2010 Feb; 59(2):224-30. PubMed ID: 19765783 [TBL] [Abstract][Full Text] [Related]
20. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]